Mackenzie Financial
AMPH icon

Mackenzie Financial’s Amphastar Pharmaceuticals AMPH Stock Holding History

Mackenzie Financial’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,592
Closed -$289K – 1537
2024
Q1 		$289K Buy
6,592
+837
+15% +$43.2K ﹤0.01% 1190
2023
Q4 		$356K Hold
5,755
– – ﹤0.01% 1100
2023
Q3 		$258K Buy
+5,755
New +$314K ﹤0.01% 1187

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mackenzie Financial's AMPH Position: Q2 2024 in Review

Mackenzie Financial sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2024, closing a stake of 6,592 shares — an estimated $289K sold.

Mackenzie Financial first reported a position in AMPH in Q3 2023 and held it in 3 quarters. The position peaked at $356K in Q4 2023. 269 funds tracked by Wall St. Rank hold AMPH as of Q2 2024.

  • Mackenzie Financial reported no remaining Amphastar Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Mackenzie Financial sold 6,592 Amphastar Pharmaceuticals shares in Q2 2024, an estimated $289K.
  • Mackenzie Financial first reported a position in Amphastar Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • Mackenzie Financial's Amphastar Pharmaceuticals position peaked at $356K in Q4 2023.
  • 269 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2024.

Based on Mackenzie Financial's 13F filing for Q2 2024, filed 14 Aug 2024.